Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zydelig

- PMLiVE

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

Roche - Basel

EMA launches probe into Roche’s adverse event reporting

Pharma company allegedly failed to follow pharmacovigilance procedures

- PMLiVE

Abbott and Seattle expand antibody-drug conjugate collaboration

Pharma company could pay $220m per oncology target

- PMLiVE

Vivus fails to get European backing for obesity treatment Qsiva

EMA raises concerns about drug’s cardiovascular safety

Bayer’s former oncology head Robert Rosen joins AP Pharma

Will lead launch of drug to prevent chemotherapy-induced nausea

- PMLiVE

Novo Nordisk files new haemophilia drug in EU, US

Seeks approval for turoctocog alfa shortly after vatreptacog alfa pulled

- PMLiVE

Lilly’s gastric cancer prospect clears phase III trial

Ramucirumab improved both overall and progress-free survival

Roche - Basel

Roche Q3 sales up on cancer drugs

And CEO Schwan commits to gene sequencing despite failed Illumina bid

Celgene’s Abraxane receives FDA approval in lung cancer

Adds to current breast cancer indication

European orphan drug applications up 30 per cent

But lower than expected generics applications see EMA reduce new marketing authorisation forecast

AZ’s MedImmune partners with global cancer institutes

Will research combinations of immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links